LANE David Philip

The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding

Current therapeutic antibodies such as Trastuzumab, are typically of the blood circulatory IgG1 class (Cκ/ CHγ1). Due to the binding to Her2 also present on normal cell surfaces, side effects such as cardiac failure can sometimes be associated with such targeted therapy. Using antibody isotype swapping, it may be possible to reduce systemic circulation through increased tissue localization, thereby minimising unwanted side effects. However, the effects of such modifications have yet to be fully characterized, particularly with regards to their biophysical properties in antigen binding.

type: 
Journal Paper
journal: 
Scientific Reports 8, Article no 718, 2018, doi:10.1038/s41598-017-18892-9
Url: 
https://www.nature.com/articles/s41598-017-18892-9?WT.feed_name=subjects_immunotherapy
Impact Factor: 
4.259
Date of acceptance: 
2017-12-19
Syndicate content